Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NeXeption, LLC
Unique market dynamics and plenty of exit options are attracting investors to dermatology. Profiles of Aclaris Therapeutics, Alexar Therapeutics, Rogne Bioscience, and Scioderm.
Alexar Therapeutics Inc. is developing a topical formulation of a Liver-X receptor agonist for atopic dermatitis, aka eczema. The company expects its formulation will safely treat the two key symptoms of this common skin disorder, by reducing inflammation on the skin surface and helping to repair the skin barrier.
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Venture Funding column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2014.
The asset-focused operator of virtual biotechs teamed with Texas early-stage investment group Remeditex to back a new entity. Tigercat has filed an IND to investigate serlopitant for chronic itching.
- Other Names / Subsidiaries
- NST, LLC
- NeXeption II, LLC.
- NST Consulting, LLC
- Ralexar Therapeutics Inc., AltheRx Pharmaceuticals Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.